Neurocrine Biosciences stockholders approve amended 2025 equity plan at annual meeting
At its annual meeting on May 27, 2026, Neurocrine Biosciences stockholders elected three Class III directors to three-year terms expiring at the 2029 meeting. They also approved an amendment to the 2025 Equity Incentive Plan, approved the compensation of named executive officers on an advisory basis, and ratified Ernst & Young LLP as the independent auditor for fiscal 2026. The plan amendment governs equity awards to employees and directors, and its material terms are described in the April 15, 2026 proxy statement.
Key points
- Shares present were 90,118,625 of 100,581,991 entitled to vote as of the March 31, 2026 record date.
- Amended 2025 Plan approved with 79,131,622 votes for, 5,568,926 against and 65,732 abstentions.
- Advisory vote on executive pay passed with 78,993,894 votes for and 5,669,155 against.
- Kevin C. Gorman, Ph.D. received 76,228,063 votes for; Gary A. Lyons received 75,278,705 and Johanna Mercier received 74,671,942.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.